Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copper Cu 64-DOTA B-Fab is a radiopharmaceutical agent composed of a humanized antibody fragment (B-Fab) conjugated to the chelator DOTA and labeled with the positron-emitting radioisotope copper-64. It is designed for use as a PET imaging tracer to evaluate expression of cancer antigen CA6 in tumors, particularly in patients with ovarian and breast cancer. The mechanism involves specific binding of the B-Fab fragment to CA6-expressing tumor cells, allowing for non-invasive visualization and localization using PET/CT imaging. This agent enables assessment of CA6 status in tumors, which may inform diagnosis or therapeutic planning[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on copper cu 64-dota b-fab.